Cassie Smith, MD
Endocrinology, Diabetes & Metabolism · Edmond, OKNPI 1578852703
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $531,562 of the $629,449 with a category attached, or 84.4%. 53 manufacturers reported payments, led by Lilly USA, LLC at 39.3% of the total. Reporting peaked in 2019 at $246,627 and has fallen 99.4% since, to $1,389 in 2025. Among endocrinology, diabetes & metabolism clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,743 payments — averaging $361.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$247K
- Boehringer Ingelheim$101K
- Novo Nordisk$91K
- Sanofi-aventis U.S. LLC$85K
- Johnson & Johnson$41K
- Dexcom, Inc.$29K
- plus $35K from 47 others
What the payments were for
- Consulting fees$14,9502%
- Speaking & faculty fees$531,56284%
- Travel & lodging$53,4678%
- Food & beverage$29,4525%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$150,906
- TRULICITY$110,118
- SOLIQUA 100/33$66,310
- MOUNJARO$48,735
- Ozempic$46,238
- RYBELSUS$40,740
- INVOKANA$40,029
- TOUJEO$40,006
- Synthroid$15,517
- DEXCOM G6 TRANSMITTER$12,776
- DEXCOM CGM$9,051
- DEXCOM G6 CGM SYSTEM$6,262
- Eversense$4,000
- Korlym$3,153
- DISEASE STATE$3,035
- EVERSENSE E3 SMART TRANSMITTER KIT$2,627
- NP Thyroid 60$990
- FARXIGA$695
- NEXLIZET$125
- NEXLETOL$125
How this compares
$629,449 in reported general payments places this provider in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $162,964 |
| TrulicityDulaglutide | 87 | $110,190 |
| MounjaroTirzepatide | 82 | $100,539 |
| JardianceEmpagliflozin | 93 | $99,349 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $61,511 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $51,215 |
| ForteoTeriparatide | 12 | $49,552 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 49 | $40,233 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $25,664 |
| FarxigaDapagliflozin Propanediol | 23 | $23,029 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $22,883 |
| KerendiaFinerenone | 26 | $22,119 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,520 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $10,297 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $9,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo | $247,450 | $260,281181 claims |
| Novo NordiskOzempic | $91,498 | $162,964122 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $100,558 | $139,582142 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $85,308 | $61,51139 claims |
| AstraZenecaFarxiga | $2,122 | $23,02923 claims |
| BayerKerendia | $795 | $22,11926 claims |
| AbbVieSynthroid, Armour Thyroid | $16,146 | $6,09065 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $239 | $4,378341 claims |
| IBSA Pharma Inc.Tirosint-Sol | $330 | $1,62112 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $1,037 | $81116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Edmond
- Matthew DraelosEdmond$110K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Christian MangrumOklahoma City$54K
- Vaqar AhmadMidwest City$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Robert ScofieldOklahoma City$15K
- Lubna MirzaNorman$12K
- Donny WynnOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.